Thetuberculosis testing marketwas valued atUSD 1.96 billion in 2024and is projected to grow fromUSD 2.09 billion in 2025to reachUSD 3.25 billion by 2033, registering a CAGR of5.5%during the forecast period. Tuberculosis, caused byMycobacteriumbacteria, primarily affects the lungs but can also damage the lymphatic system, central nervous system, and other organs. With TB incidence continuing to rise, the demand for effective and fast diagnostic kits is stronger than ever.
Governments and healthcare organizations are ramping up investments to control TB through better diagnosis and treatment access. For instance, according to Indias TB report 2022, the number of incident TB patients surged by19% in 2021compared to 2020. This highlights why advanced diagnostic tools and awareness initiatives are becoming critical to reducing TB cases worldwide.
Key Market Drivers
Favorable government policies:Countries with high TB burdens are prioritizing stronger diagnostic frameworks and awareness campaigns.
Technological advancements:Rapid molecular diagnostics, IGRA tests, and cartridge-based nucleic acid amplification technologies are making detection faster and more reliable.
Rising prevalence of TB and MDR-TB:High incidence in regions like India and sub-Saharan Africa is creating strong demand for early diagnosis and accurate testing.
Regional Insights
North Americaholds the largest market share due to high RD spending, strong presence of leading players, and the prevalence of HIV-linked TB cases.
Europebenefits from government-backed initiatives and rising demand for molecular diagnostics.
Asia-Pacificis the fastest-growing region, fueled by Indias high TB burden, government campaigns, and healthcare infrastructure improvements.
LAMEAis expected to see substantial growth, supported by better healthcare facilities, aging populations, and international TB eradication programs.
Diagnostic Test Type Analysis
Rapid molecular diagnosticsdominate the market due to their speed and accuracy.
Culture-based testsare also gaining traction as more advanced and efficient testing methods emerge.
End-User Analysis
Hospitalslead the market as they remain the primary centers for TB diagnosis and treatment.
Diagnostic laboratoriesare expanding rapidly, thanks to rising awareness and demand for specialized TB testing services.
Key Players in the Tuberculosis Testing Market
Abbott Laboratories
Becton Dickinson Company
BioMerieux SA
Cepheid
F. Hoffmann-La Roche AG
Hain LifeScience GmbH
Hologic Corporation
Qiagen
AdvaCare Pharma
Thermo Fischer Scientific
Recent Developments
October 2022:Illumina Inc. partnered with GenoScreen to expand global access to sequencing-based TB diagnostics, enabling faster detection of multidrug-resistant TB.
January 2021:PerkinElmer acquired Oxford Immunotec, adding the T-SPOT TB test to its infectious disease diagnostics portfolio.
The rising TB burden, combined with innovation in diagnostic technologies, is setting the stage for strong market growth. Companies that can provide faster, more accurate, and accessible solutions are expected to gain a competitive edge in the coming years.
About Us:
Straits Research is a leading global market intelligence and consulting firm, dedicated to delivering actionable insights and in-depth analysis across a wide range of industries. Our mission is to empower organizations, investors, and decision-makers with reliable data, strategic guidance, and forward-looking perspectives to help them thrive in a rapidly evolving business landscape.
Contact Us:
Email:sales@straitsresearch.com
Tel: +1 646 905 0080 (U.S.), +44 203 695 0070 (U.K.)
Website:https://straitsresearch.com/
